Argyria

Back

Background

Argyria results from prolonged contact with or ingestion of silver salts. Argyria is characterized by gray to gray-black staining of the skin and mucous membranes produced by silver deposition. Silver may be deposited in the skin either from industrial exposure or as a result of medications containing silver salts. See the image below.



View Image

A 92-year-old asymptomatic white man with generalized argyria. For many years, this man had used nose drops containing silver. His skin biopsy showed ....

See Clues on the Skin: Acute Poisonings, a Critical Images slideshow, to help diagnose patients based on their dermatologic presentations.

The most common cause of argyria is mechanical impregnation of the skin by small silver particles in workers involved in silver mining, silver refining, silverware and metal alloy manufacturing, metallic films on glass and china, electroplating solutions, and photographic processing. Colloidal silver dietary supplements are marketed widely for cancer, AIDS, diabetes mellitus, and herpetic infections.[1, 2, 3] Cases have followed the prolonged use of silver salts for the irrigation of urethral or nasal mucous membranes, in eye drops, wound dressing, and the excessive use of an oral smoking remedy containing silver acetate.[4, 5]

Argyria has also been attributed to surgical and dental procedures (eg, silver amalgam-tattooing, silver sutures used in abdominal surgery). Blue macules have appeared at sites of acupuncture needles and silver earring sites.[6, 7] Great individual variability exists in the length of exposure and total dose needed to result in argyria.

Pathophysiology

Localized argyria occurs in the conjunctiva or oral mucous membrane after long-term topical treatment with silver salt solutions or short-contact acupuncture.

Universal argyria can develop after long-term systemic treatment with drugs that contain silver salts. This used to occur in patients who had taken silver protein suspension for chronic gastritis or gastric ulcer or as nose drops.[8] Argyria also happens as an occupational disease in workers who prepare artificial pearls or who are employed in the cutting and polishing of silver (absorption of silver dust).

The normal human body contains approximately 1 mg of silver; the smallest amount of silver reported to produce generalized argyria in humans ranges from 4-5 g to 20-40 g. Silver at 50-500 mg/kg body weight is the lethal toxic dose in humans.

Bianchi et al report a possible genetic predisposition for argyria.[9]

Etiology

Although pigmentary changes occur primarily in sun-exposed sites, granules are evenly deposited throughout all skin. Differing theories exist as to why the blue-gray pigmentation is restricted to sun-exposed sites. Some believe that silver compounds complexed with proteins in the skin are reduced to elemental silver by light, similar to the process of photo imaging.[10] Others contend that silver plus light stimulates melanogenesis, which results in the blue-gray color.

Epidemiology

Argyria has become a rare dermatosis, mainly because of the avoidance of silver-containing compounds as medicinals and a decrease in occupational exposure in the silver industry. Exposure to silver was common in the early part of this century. The famous Blue Man, a member of the Barnum and Bailey Circus sideshow, had a classic case of argyria.

Prognosis

A permanent and irreversible metallic tinge occurs in the skin of patients with argyria.

History

A careful history is necessary. Be sure to inquire about possible occupational and environmental exposure, the use of dietary supplements in general, and colloidal silver protein dietary supplements in particular.

Habitual use of silver-based nose drops may produce pigmentation most apparent on the nose and the nail lunulae.[11]

Scar-localized argyria may occur secondary to silver sulfadiazine cream.[12]

Physical Examination

Early on, a gray-brown staining of the gums develops, later progressing to involve the skin diffusely. The cutaneous pigmentation usually is a slate-gray, metallic, or blue-gray color and may be clinically apparent after a few months, but clinical appearance usually takes many years and depends on the degree of exposure.

The hyperpigmentation is most apparent in the sun-exposed areas of skin, especially the forehead, nose, and hands.

In some patients, the entire skin acquires a slate blue-gray color.

The sclerae, nail beds, and mucous membranes may become hyperpigmented.

Viscera tend to show a blue discoloration, including the spleen, liver, and gut, findings evident during abdominal surgery or at postmortem examination.

Rarely, black tears (melanodacryorrhea) can appear during argyrosis of the conjunctiva.

Complications

The systemic toxic effects of silver may include the following:

Current thought holds that the substantial amounts of silver in argyria usually result in no serious effects on human health. However, a few cases have notable clinical symptoms and signs. This lack of significant systemic silver toxicity in argyria may be due to the interaction of selenium and sulfur with silver in vivo.

It was reported that argyria can be associated with unexpected and quickly developing severe radiation dermatitis during chemoradiotherapy treatment.[13]

Imaging Studies

In vivo silver concentrations can be measured using x-ray fluorescence.[16]

Dermoscopy, reflectance confocal microscopy, and high-definition optical coherence tomography can be used in the diagnosis of generalized argyria.[17, 18]

Corneal confocal microscopy and electrophysiological tests may help confirm the diagnosis of ocular argyrosis.[19]

Procedures

The diagnosis of argyria is established by skin biopsy with formaldehyde-fixed paraffin-embedded sections stained with hematoxylin-eosin.

Histologic Findings

Small, round, brown-black granules appear singly or in clusters and are evident with routine staining. They spare both the epidermis and its appendages, appearing in greatest numbers in the basement membrane zone surrounding sweat glands. These silver granules also favor the connective-tissue sheaths around pilosebaceous structures and nerves. They have a predilection for elastic fibers and are best visualized as strikingly refractile with dark-field illumination. An increase in the amount of melanin in exposed skin also appears to occur.

Electron microscopy demonstrates electron-dense granules. In early cases, they are located within fibroblasts and macrophages, while later most are present extracellularly. Neutron activation analysis, atomic absorption spectrophotometry, or x-ray dispersive microanalysis can be used to confirm that the granules contain silver and often also sulfur and less commonly selenium.[20, 21, 22] A simpler option is to decolorize the silver by placing histologic sections into 1% potassium ferricyanide in 20% sodium thiosulfate.

Medical Care

Treatment with depigmenting preparations is not satisfactory; however, according to some reports, 5% hydroquinone treatment may reduce the number of silver granules in the upper dermis and around sweat glands and diminish the number of melanocytes.

Chelation attempts to remove silver from the body have been unsuccessful.

Sunscreens and opaque cosmetics may be helpful in preventing further pigmentary darkening and aid in masking obvious discoloration.

Surgical Care

The treatment of argyria caused by colloidal silver ingestion using the Q-switched 1064-nm Nd:YAG laser has been reported,[23, 24] and a picosecond 755-nm Q-switched alexandrite laser has also been used with success for treatment.[25, 26]

Medication Summary

Selenium and sulfur have been shown to have favorable modifying effects on the metabolism and toxicity of silver by forming complexes with silver. Silver selenide is highly insoluble in vivo, and this effectively reduces the availability of monovalent silver to interfere with normal enzymatic activities in tissues. However, the silver-sulfur complexes formed in vivo do not seem as stable as silver-selenium complexes.

Hydroquinone (Eldopaque-Forte, Solaquin Forte, Lustra)

Clinical Context:  Topical application produces a reversible depigmentation of the skin by the inhibition of the enzymatic oxidation of tyrosine to 3,4-dihydroxyphenylalanine and suppression of the melanocyte metabolic process.

Class Summary

According to reports, a 4% hydroquinone treatment could reduce the number of silver granules in the upper dermis and around sweat glands and reduce the number of melanocytes; however, no completely satisfactory treatment modalities exist and some pigmentation remains permanently.

Author

Kamila K Padlewska, MD, PhD, Professor, Warsaw Academy of Cosmetics and Health Care; Chief Executive, Cosmetic-Medical Cooperative Izis, Poland

Disclosure: Nothing to disclose.

Coauthor(s)

Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Pathology, Professor of Pediatrics, Professor of Medicine, Rutgers New Jersey Medical School

Disclosure: Nothing to disclose.

Specialty Editors

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Disclosure: Nothing to disclose.

Jeffrey J Miller, MD, Associate Professor of Dermatology, Pennsylvania State University College of Medicine; Staff Dermatologist, Pennsylvania State Milton S Hershey Medical Center

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD.

Acknowledgements

Smeena Khan, MD Private Practice, Adult and Pediatric Dermatology Associates

Smeena Khan, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

References

  1. Bouts BA. Images in clinical medicine. Argyria. N Engl J Med. 1999 May 20. 340(20):1554. [View Abstract]
  2. Fung MC, Bowen DL. Silver products for medical indications: risk-benefit assessment. J Toxicol Clin Toxicol. 1996. 34(1):119-26. [View Abstract]
  3. Gulbranson SH, Hud JA, Hansen RC. Argyria following the use of dietary supplements containing colloidal silver protein. Cutis. 2000 Nov. 66(5):373-4. [View Abstract]
  4. Brandt D, Park B, Hoang M, Jacobe HT. Argyria secondary to ingestion of homemade silver solution. J Am Acad Dermatol. 2005 Aug. 53(2 Suppl 1):S105-7. [View Abstract]
  5. Gaslin MT, Rubin C, Pribitkin EA. Silver nasal sprays: misleading Internet marketing. Ear Nose Throat J. 2008 Apr. 87(4):217-20. [View Abstract]
  6. Legat FJ, Goessler W, Schlagenhaufen C, Soyer HP. Argyria after short-contact acupuncture. Lancet. 1998 Jul 18. 352(9123):241. [View Abstract]
  7. Rackoff EM, Benbenisty KM, Maize JC, Maize JC Jr. Localized cutaneous argyria from an acupuncture needle clinically concerning for metastatic melanoma. Cutis. 2007 Nov. 80(5):423-6. [View Abstract]
  8. Prescott RJ, Wells S. Systemic argyria. J Clin Pathol. 1994 Jun. 47(6):556-7. [View Abstract]
  9. Bianchi L, Orlandi A, Di Stefani A, Ricci R, Chimenti S. "Familial" generalized argyria. Arch Dermatol. 2006 Jun. 142(6):789-90. [View Abstract]
  10. Shelley WB, Shelley ED, Burmeister V. Argyria: the intradermal "photograph," a manifestation of passive photosensitivity. J Am Acad Dermatol. 1987 Jan. 16(1 Pt 2):211-7. [View Abstract]
  11. Menaguale G, Fazio R, Fazio M. Argyria: a case following the prolonged use of a rhinologic drug. Esper Dermatol (Roma). 2003. 4:299-303.
  12. Fisher NM, Marsh E, Lazova R. Scar-localized argyria secondary to silver sulfadiazine cream. J Am Acad Dermatol. 2003 Oct. 49(4):730-2. [View Abstract]
  13. Gorayski P, Pinkham MB, Muir JB, Pullar AP. Severe acute radiation dermatitis in a patient with argyria. Case Rep Oncol Med. 2014. [View Abstract]
  14. Alés-Fernández M, Ríos-Martín JJ, Camacho-Martínez FM. Localized argyria secondary to acupuncture mimicking blue nevus. J Drugs Dermatol. August 2010. 9(8):1019-20. [View Abstract]
  15. Enei ML, Paschoal FM, Valdés R. Argyria mimicking a blue nevis: dermoscopy features. An Bras Dermatol. 2013 Jun. 88(3):[View Abstract]
  16. Graham SA, O'Meara JM. The feasibility of measuring silver concentrations in vivo with x-ray fluorescence. Phys Med Biol. 2004 Aug 7. 49(15):N259-66. [View Abstract]
  17. Cinotti E, Labeille B, Douchet C, Cambazard F, Perrot JL. Dermoscopy, reflectance confocal microscopy, and high-definition optical coherence tomography in the diagnosis of generalized argyria. J Am Acad Dermatol. 2017 Feb. 76 (2S1):S66-S68. [View Abstract]
  18. García-Martínez P, López Aventín D, Segura S, Gómez-Martín I, Lloreta J, Ibáñez J, et al. In vivo reflectance confocal microscopy characterization of silver deposits in localized cutaneous argyria. Br J Dermatol. 2016 Nov. 175 (5):1052-1055. [View Abstract]
  19. Sarnat-Kucharczyk M, Pojda-Wilczek D, Mrukwa-Kominek E. Diagnostic methods in ocular argyrosis: case report. Doc Ophthalmol. 2016 Oct. 133 (2):129-138. [View Abstract]
  20. Lee SM, Lee SH. Generalized argyria after habitual use of AgNO3. J Dermatol. 1994 Jan. 21(1):50-3. [View Abstract]
  21. Robinson-Bostom L, Pomerantz D, Wilkel C, et al. Localized argyria with pseudo-ochronosis. J Am Acad Dermatol. 2002 Feb. 46(2):222-7. [View Abstract]
  22. Sato S, Sueki H, Nishijima A. Two unusual cases of argyria: the application of an improved tissue processing method for X-ray microanalysis of selenium and sulphur in silver-laden granules. Br J Dermatol. 1999 Jan. 140(1):158-63. [View Abstract]
  23. Rhee DY, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK. Treatment of argyria after colloidal silver ingestion using Q-switched 1,064-nm Nd:YAG laser. Dermatol Surg. 2008 Oct. 34(10):1427-30. [View Abstract]
  24. Han TY, Chang HS, Lee HK, Son SJ. Successful treatment of argyria using a low-fluence Q-switched 1064-nm Nd:YAG laser. Int J Dermatol. 2011 Jun. 50 (6):751-3. [View Abstract]
  25. Friedmann DP, Buckley S, Mishra V. Localized Cutaneous Argyria From a Nasal Piercing Successfully Treated With a Picosecond 755-nm Q-Switched Alexandrite Laser. Dermatol Surg. 2017 Aug. 43 (8):1094-1095. [View Abstract]
  26. DiGiorgio CM, Wu DC, Goldman MP. Successful Treatment of Argyria Using the Picosecond Alexandrite Laser. Dermatol Surg. 2016 Mar. 42 (3):431-3. [View Abstract]

A 92-year-old asymptomatic white man with generalized argyria. For many years, this man had used nose drops containing silver. His skin biopsy showed silver deposits in the dermis, confirming the diagnosis of argyria. © Dec 3, 2008 Herbert L. Fred, MD; Hendrik A. van Dijk. Textbook content produced by Herbert L. Fred, MD; Hendrik A. van Dijk is licensed under a Creative Commons Attribution License 2.0 license.

A 92-year-old asymptomatic white man with generalized argyria. For many years, this man had used nose drops containing silver. His skin biopsy showed silver deposits in the dermis, confirming the diagnosis of argyria. © Dec 3, 2008 Herbert L. Fred, MD; Hendrik A. van Dijk. Textbook content produced by Herbert L. Fred, MD; Hendrik A. van Dijk is licensed under a Creative Commons Attribution License 2.0 license.